> PolyProx Therapeutics, a University of Cambridge spinout, raised £3.4 million ($4.4 million) to work on drugs that engage cellular degradation machinery to stop tumor growth. Release
> 4D Pharma completed an early part of its phase 1/2 Keytruda combination trial without seeing dose-limiting toxicities. Statement
> Freeline Therapeutics struck a multi-year agreement with Brammer Bio to secure access to gene therapy production capacity in the U.S. The capacity will support potential commercial demand for hemophilia B gene therapy FLT180a. Release
> Baylor College of Medicine presented data on its Cell Medica-partnered GD2-CAR NKT cells. One of two patients treated with the lowest dose of the drug experienced “extensive tumor regression at four weeks.” Statement
> Amal Therapeutics teamed up with Boehringer Ingelheim to test its ATP128 in combination with anti-PD-1 antibody BI754091. Release
> Numab offloaded the Chinese rights to a trispecific antibody-based molecule targeting PD-L1, 4-1BB and human serum albumin to CStone Pharmaceuticals. Statement